Search Results for: VTGN

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an Equity Research Company Update by Maxim Group LLC. The report, titled “Benzo-Benefits Without the Benzo-Baggage – The Case for PH94B Builds,” highlights potential benefits of VistaGen’s PH94B drug candidate, a … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Equity Research Company Update”

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, recently announced positive new data from the company’s second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. According to the update, results of the new study complement previous preclinical data … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 – Probenecid Combination”

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (“CNS”) diseases and disorders with high unmet need, today announced that it has received Fast Track designation U.S. Food and Drug Administration (“FDA”) for development of the company’s PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics, Inc.’s (NASDAQ: VTGN) PH94B Receives FDA Fast Track Designation to Treat Social Anxiety Disorder”

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (“CNS”) diseases and disorders with high unmet need, this morning announced the appointment of Michael Liebowitz, M.D. to the company’s CNS Clinical and Regulatory Advisory Board. The addition of Dr. Liebowitz seamlessly aligns with VistaGen’s preparation for its pivotal … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Names New Member of CNS Clinical and Regulatory Advisory Board”

VistaGen Therapeutics (NASDAQ: VTGN) recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for development of AV-101 as a non-opioid, non-sedating treatment for neuropathic pain, marking the second Fast Track designation granted to the company since December 2017. This designation facilitates the development, and possibly accelerate the review, of … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Obtains Fast Track Designation on AV-101 to Treat Neuropathic Pain”

Clinical-stage biopharmaceutical company VistaGen Therapeutics (NASDAQ: VTGN) recently announced that it has been issued U.S. Patent No. 9,834,801 by the U.S. Patent and Trademark Office (“USPTO”), strengthening its intellectual property (“IP”) stance. The newly-issued patent covers certain methods of production for AV-101, VistaGen’s lead central nervous system (“CNS”) product candidate. “This issued U.S. patent, in … Continue reading “NetworkNewsBreaks – VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Advances IP for Lead Product Candidate with New Methods of Production Patent”